This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
November 1, 2011 04:30 pm ET
Pete Meldrum – President and CEO
Mark Capone – President, Myriad Genetic Laboratories
Jim Evans – Chief Financial Officer
Rebecca Chambers – Director of Investor Relations
Scott Gleason – Stephens, Inc.
Jon Wood – Jefferies & Company
Amanda Murphy – William Blair & Company
Tycho Peterson – JP Morgan
Michael Yee – RBC Capital Markets
Isaac Ro – Goldman Sachs
Dave [Kler] – Piper Jaffray
Ashim Anand – Natixis Bleichroeder
Peter Larson – Mizuho Securities
Laura McGuigan – B. Riley
Welcome to Myriad Genetics’ FQ1 Earnings Call. (Operator instructions.) As a reminder, this conference is being recorded Tuesday, November 1, 2011. I would now like to turn the conference over to Rebecca Chambers, Director of Investor Relations. Please go ahead, ma’am.
Thank you, Lindsey. Good afternoon, everyone, and welcome to the Myriad Genetics’ FQ1 2012 Earnings Call. During the call we will review the financial results we released today and the progress we have made on our strategic directives, after which we will host a question-and-answer session. If you have not had a chance to review the earnings release it can be found in the Investor Relations section of our website at
Presenting today will be Pete Meldrum, President and Chief Executive Officer; Mark Capone, President, Myriad Genetic Laboratories; and Jim Evans, our Chief Financial Officer. This call can be heard live via webcast along with the slide presentation at
www.myriad.com. The call is being recorded and will be archived in the Investor section of our website.
Please note that some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations for a variety of reasons. We refer you to the documents the company files from time to time with the Securities and Exchange Commission, specifically the company’s annual report on Form 10(k), its quarterly reports on Form 10(q), and its current reports on Form 8(k). These documents identify important risk factors that could cause the actual results to differ materially from those contained in our projections or forward-looking statements.